Published: 1 November 2019
Author(s): Rajkumar Doshi, Zahara Meghji, Ashish Kumar, Mariam Shariff, Devina Adalja
Section: Letter to the Editor

Sodium-Glucose co-transporter 2 inhibitors (SGLT2i) are novel therapeutic agents used for the treatment of type 2 diabetes mellitus (T2DM) and have reno-protective effects in patients with T2DM with or without renal impairment [1]. One of the previous meta-analysis included only 3 trials which showed reduction in major adverse cardiac events by 11% [2]. There were new trials published showing beneficial effects of SGLT2 inhibitors after this meta-analysis. Therefore, we have performed a meta-analysis including those trials to analyze if beneficial effects of SGLT2i still persist.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.